Last updated: February 26, 2026
What is the role of excipients in OMNIPAQUE formulation?
OMNIPAQUE (iodixanol) is an iodinated contrast agent used for diagnostic imaging. Its formulation incorporates specific excipients that influence stability, osmolarity, viscosity, and injection safety. Excipients in OMNIPAQUE include:
- Glucose (used for stabilizing the formulation)
- Sodium chloride (for isotonicity)
- Sodium hydroxide or hydrochloric acid (for pH adjustment)
- Water for injection (solvent)
These excipients ensure the drug's physical stability, compatibility with injection devices, and patient safety. The formulation’s osmolarity—approximately 290 mOsm/kg—closely matches plasma osmolarity, reducing adverse reactions.
How does excipient selection impact OMNIPAQUE’s pharmacokinetic and safety profile?
Excipients affect osmolarity, viscosity, and pH, which influence the drug’s safety and tolerability:
- Viscosity: Affects injection ease; OMNIPAQUE's viscosity ranges from 11.8 to 14.8 cP depending on concentration, influenced by excipients.
- Osmolarity: Isotonicity minimizes pain, hemorrhage, or allergic reactions. Excipients like sodium chloride help maintain osmolarity.
- pH: Typically around 6.3, adjusted with sodium hydroxide or hydrochloric acid to enhance stability and reduce tissue irritation.
Alterations in excipient composition can improve patient comfort, reduce adverse events, or enable new administration routes.
What are the recent innovations in excipient strategies for contrast agents?
Interest lies in developing excipient formulations that:
- Reduce viscosity to enable lower injection force, especially for high-concentration formulations.
- Lower osmolality below current levels to increase tolerability.
- Incorporate surfactants or stabilizers to extend shelf-life and stability.
- Use biodegradable or biocompatible excipients to enhance safety profiles.
For example, some contrast agents are exploring amino acid-based buffers or sugar derivatives for better tolerability.
What commercial opportunities exist with excipient modifications in OMNIPAQUE?
Opportunities include:
- Formulation improvements: Developing lower-viscosity, lower-osmolality versions could expand indications, such as in pediatric imaging or high-volume administrations, increasing market share.
- Reduced adverse events: Enhancing tolerability can decrease hospital stays and post-procedure complications.
- New delivery modes: Formulations optimized for subcutaneous or intraarterial use may open new clinical applications.
- Patent protection: Reformulated products with novel excipient profiles can secure new IP rights, extending product lifecycle.
Partnering with excipient suppliers or investing in custom excipient development offers strategic advantages.
What regulatory considerations influence excipient choices for OMNIPAQUE?
Regulatory agencies such as the FDA and EMA enforce strict standards for excipients:
- Approval of excipient safety profiles.
- Justification of excipient use in new formulations.
- Labeling requirements clarifying excipient content.
- Compatibility testing for drug-excipient interactions.
Any reformulation leveraging new excipients must undergo regulatory submission and validation, affecting time-to-market.
How do competitive contrast agents utilize excipient strategies?
Other contrast agents employ excipient modifications to differentiate:
- Visipaque (iodixanol): Similar composition to OMNIPAQUE but with potential formulation tweaks for improved tolerability.
- Ultravist (iopromide): Higher osmolality, with different excipient profiles aimed at different clinical settings.
- Optiray (ioversol): Uses alternative excipients to modulate viscosity and osmolality.
These strategies reflect ongoing efforts to balance efficacy, safety, and patient comfort.
Key Takeaways
- Excipient selection in OMNIPAQUE influences stability, osmolarity, viscosity, and safety.
- Innovations focus on reducing viscosity and osmolality to improve tolerability, particularly important for pediatric and high-volume uses.
- Excipient strategy offers pathways for formulation improvements, new indications, and patent extensions.
- Regulatory approval remains a key step in implementing excipient modifications.
- Competitive landscape demonstrates active development of contrast agents with optimized excipient profiles to address safety and comfort.
FAQs
Q1: Can changing excipients in OMNIPAQUE improve patient comfort?
Yes. Adjustments that lower viscosity or osmolarity can reduce injection pain and adverse reactions.
Q2: Are new excipient formulations likely to be more expensive?
Potentially. Novel excipients or reformulation costs may increase prices, but improvements in safety and patient tolerability can offset this.
Q3: What regulatory hurdles exist for reformulating OMNIPAQUE?
Reformulations require demonstrating bioequivalence, safety, and stability, necessitating new clinical and stability studies.
Q4: Is there a market demand for contrast agents with lower osmolality?
Yes. Lower osmolality contrast media are associated with fewer adverse effects, especially in high-risk patients.
Q5: How can excipient modifications expand OMNIPAQUE’s clinical applications?
By improving tolerability, formulations could be suitable for pediatric, outpatient, or high-volume imaging procedures.
References
[1] Food and Drug Administration. (2021). Guidance for Industry - Chemistry, Manufacturing, and Controls Changes to an Approved NDA or ANDA.
[2] EMEA (European Medicines Agency). (2019). Guideline on the Specification Limits for Residues of Pharmacologically Active Substances (Residual LIKEs).
[3] U.S. Pharmacopoeia. (2022). Pharmaceutical Excipients Monograph.
